Literature DB >> 32772218

Alternative mydriasis techniques for retinopathy of prematurity screening.

Aikaterini K Seliniotaki1, Efthymia Prousali1, Maria Lithoxopoulou2, Stamatia Kokkali3, Nikolaos Ziakas1, Vasiliki Soubasi2, Asimina Mataftsi4.   

Abstract

PURPOSE: There is a large variation in mydriatic regimens used in screening for retinopathy in preterm infants. Except for the standard instillation of mydriatic drops in their commercial formulation, other techniques for pupil dilation have also been described. This study aimed to review all techniques that have been used for mydriasis in retinopathy of prematurity eye examination (ROPEE) screening.
METHODS: A comprehensive literature search was performed in PubMed, Cochrane library, Trip database, and Scopus, using the key words: "mydriasis", "techniques", "mydriatics", "dilating drops", "retinopathy of prematurity", "ROP", "phenylephrine", "cyclopentolate", "tropicamide", "smaller mydriatic drops", "reduction in drop size" to February 2019.
RESULTS: Five primary studies were included, assessing the techniques of microdrops, lower conjunctival fornix (LCF) packing and Mydriasert® ophthalmic insert. Reported efficacy was similar to commercial eyedrops instillation. Microdrops appeared to have a superior safety profile. LCF packing and Mydriasert lead to increased blood pressure, without serious complications, necessitating further safety studies.
CONCLUSIONS: Of all alternative mydriasis techniques for ROPEE screening that have been described, microdrops appear to be the safest yet still effective technique in the fragile population of premature infants in risk of ROP.

Entities:  

Keywords:  Dilation; Mydriasis; Mydriatics; Preterm infants; Retinopathy of prematurity

Mesh:

Substances:

Year:  2020        PMID: 32772218     DOI: 10.1007/s10792-020-01542-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  7 in total

1.  The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants.

Authors:  O Elibol; T Alçelik; N Yüksel; Y Caglar
Journal:  Acta Ophthalmol Scand       Date:  1997-04

2.  Effects of physical activity on risk factors for coronary heart disease in previously sedentary women: a five-year longitudinal study.

Authors:  A W Sedgwick; A H Davidson; R E Taplin; D W Thomas
Journal:  Aust N Z J Med       Date:  1988-06

3.  Reduction in mydriatic drop size in premature infants.

Authors:  S Wheatcroft; A Sharma; J McAllister
Journal:  Br J Ophthalmol       Date:  1993-06       Impact factor: 4.638

4.  Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial.

Authors:  Dominique Bremond-Gignac; Evelyne Jacqz-Aigrain; Hendy Abdoul; Alejandra Daruich; Ariel Beresniak; Olivier Baud; Corinne Alberti
Journal:  Neonatology       Date:  2018-11-27       Impact factor: 4.035

5.  Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption.

Authors:  M G Lynch; R H Brown; S M Goode; R D Schoenwald; D S Chien
Journal:  Arch Ophthalmol       Date:  1987-10

6.  Lower conjunctival fornix packing for mydriasis in premature infants: a randomized trial.

Authors:  Onsiri Thanathanee; Tanapat Ratanapakorn; Michael G Morley; Yosanan Yospaiboon
Journal:  Clin Ophthalmol       Date:  2012-02-15

7.  Systematic review of mydriatics used for screening of retinopathy in premature infants.

Authors:  Lisa Jean Kremer; David M Reith; Natalie Medlicott; Roland Broadbent
Journal:  BMJ Paediatr Open       Date:  2019-05-09
  7 in total
  1 in total

1.  Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial.

Authors:  Aikaterini K Seliniotaki; Anna-Bettina Haidich; Maria Lithoxopoulou; Helen Gika; Eleftheria Boutou; Christina Virgiliou; Martha Nikolaidou; Aristides Dokoumetzidis; Nikolaos Raikos; Elisavet Diamanti; Nikolaos Ziakas; Asimina Mataftsi
Journal:  Trials       Date:  2022-04-15       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.